Marinomed Biotech Aktie 44956022 / ATMARINOMED6
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Trading-Depot | Watchlist |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
|
06.10.2025 14:56:43
|
EQS-Adhoc: Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
|
EQS-Ad-hoc: Marinomed Biotech AG / Key word(s): Strategic Company Decision Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only. End of Inside Information Information and Explanation of the Issuer to this announcement: Ad hoc announcement Marinomed Biotech AG begins reviewing strategic options for the Marinosolv platform
Korneuburg, October 6, 2025 - Ad hoc announcement Following the successful recent capital measures, the Management Board of Marinomed Biotech AG, with the approval of the Supervisory Board, today decided to begin reviewing strategic options for the Marinosolv platform. Depending on the progress of the review, the evaluation process could include strategic partnerships for the two projects Budesolv and Tacrosolv, as well as the involvement of a strategist. Marinomed is working with an experienced consulting firm to support this process.
+++ End of ad-hoc announcement +++
About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline. The Company develops innovative patent-protected products based on the Marinosolv® platform. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The Company is headquartered in Korneuburg, Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For further information, please visit: https://www.marinomed.com.
For further inquiries contact:
Disclaimer This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed and Marinosolv® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.
06-Oct-2025 CET/CEST News transmitted by EQS Group. www.eqs.com |
| Language: | English |
| Company: | Marinomed Biotech AG |
| Hovengasse 25 | |
| 2100 Korneuburg | |
| Austria | |
| Phone: | +43 2262 90300 |
| E-mail: | office@marinomed.com |
| Internet: | www.marinomed.com |
| ISIN: | ATMARINOMED6 |
| WKN: | A2N9MM |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange (Official Market) |
| EQS News ID: | 2208704 |
| End of Announcement | EQS News Service |
|
|
2208704 06-Oct-2025 CET/CEST
Nachrichten zu Marinomed Biotech AG
|
21.11.25 |
Angespannte Stimmung in Wien: ATX Prime präsentiert sich zum Handelsende leichter (finanzen.ch) | |
|
21.11.25 |
Schwache Performance in Wien: ATX Prime präsentiert sich nachmittags leichter (finanzen.ch) | |
|
21.11.25 |
Schwacher Handel in Wien: ATX Prime notiert im Minus (finanzen.ch) | |
|
21.11.25 |
Schwache Performance in Wien: ATX Prime verbucht zum Start Verluste (finanzen.ch) | |
|
20.11.25 |
Freundlicher Handel in Wien: ATX Prime beendet den Handel im Plus (finanzen.ch) | |
|
20.11.25 |
Gewinne in Wien: ATX Prime am Donnerstagnachmittag in der Gewinnzone (finanzen.ch) | |
|
20.11.25 |
Börse Wien: ATX Prime am Mittag fester (finanzen.ch) | |
|
20.11.25 |
Donnerstagshandel in Wien: ATX Prime beginnt Handel im Plus (finanzen.ch) |
Analysen zu Marinomed Biotech AG
Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929
Könnte der aktuelle KI-Boom an den Börsen in einen Crash münden – ähnlich wie 1929 oder zur Dotcom-Blase? 📉💻
In diesem spannenden Gespräch mit Tim Schäfer sprechen wir über Parallelen zum historischen Börsencrash, die massive Überbewertung vieler Tech- und KI-Aktien wie Nvidia, Palantir oder Microsoft – und was das für Langfristanleger bedeutet. Ist der Hype finanziell überhaupt noch tragbar? Wie positionieren sich Insider und Grossinvestoren wie Warren Buffett oder Peter Thiel?
💬 Welche Risiken birgt der aktuelle KI-Hype?
💬 Was sagen Insiderverkäufe und Bewertungen über die Marktlage?
💬 Wie sollte man sich als Privatanleger jetzt aufstellen?
Ein Interview für alle, die sich fragen: Ist das noch Wachstum oder schon Wahnsinn?
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Aktien in diesem Artikel
| Marinomed Biotech AG | 19.65 | 0.00% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
Unsicherheit über US-Zinspolitik: SMI dank Schwergewichten letztlich fester -- DAX schliesst mit Abgaben -- Wall Street zum Handelsende fest -- Asiens Börsen gehen tiefrot ins WochenendeAm heimischen Aktienmarkt fassten Anleger nach tiefrotem Start wieder Mut. Der deutsche Aktienmarkt kämpfte unterdessen mit Verlusten. Die Wall Street verzeichnete Gewinne. In Fernost dominierten am Freitag die Bären.